Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration

Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of β-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied Imeglimin protective effects on hyperglycemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Detaille, D, Vial, G, Borel, A-L, Cottet-Rouselle, C, Hallakou-Bozec, S, Bolze, S, Fouqueray, P, Fontaine, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979505/
https://www.ncbi.nlm.nih.gov/pubmed/27551496
http://dx.doi.org/10.1038/cddiscovery.2015.72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979505/
https://www.ncbi.nlm.nih.gov/pubmed/27551496
http://dx.doi.org/10.1038/cddiscovery.2015.72

Ejemplares similares